butolame

modified ESTRADIOL with amino-alcohol side chain at the C17 position; has anticoagulant & estrogenic effects; structure given in first source

Also Known As:

17 beta-(4'-hydroxy-1'-butylamino)-1,3,5(10)-estratriene-3-ol; 17 beta-(4-hydroxy-1-butylamino)-1,3,5(10)-estratrien-3-ol

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Lordosis 01/01/2009 - "This work evaluates the influence of single and multiple administration of a homologous series of the AEs: prolame, butolame and pentolame on rat female sexual behavior to explore their capability of inducing lordosis by themselves. " 03/23/2009 - "Dose-response curves were performed in rats by single subcutaneous (s.c.) injection (timezero) of: E2 (approximately 0.3, 3, 30, 60, 300 microg/kg); EB (approximately 0.4, 4, 40, 80, 400 microg/kg); prolame, butolame, pentolame (approximately 40, 400, 2000 or 4000 mg/kg), vehicle (corn oil; 300 microL/day; approximately 1.2 mL/kg) as control; 24 h after, P (1 mg/rat in 100 microL of corn oil; approximately 4 to 5 mg/kg) was administered, and 5 to 7 h later LQ was evaluated (number of lordosis displays/number of mounts x 100). "
2.	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/01/2022 - "Thus, our data suggest that butolame and pentolame, but not prolame, could be used for HRT without presenting a potential risk of inducing breast- or cervical-cancer-cell proliferation. " 01/01/2022 - "Prolame induced cell proliferation in breast (MCF-7) and cervical cancer (SIHA) cells; meanwhile, butolame and pentolame did not affect cell proliferation. "